Headlines

Why Is Cancer Drug Developer Revolution Medicines Stock Trading Higher On Monday?

Revolution Medicines shared Phase 1 data showing zoldonrasib’s acceptable safety profile in KRAS G12D mutant solid tumors at AACR 2025.

read more

Leave a Reply

Your email address will not be published. Required fields are marked *